Literature DB >> 17034024

Profound thrombocytopenia related to G-CSF.

Jason C Kovacic1, Peter Macdonald, Judith Freund, John E J Rasko, Roger Allan, Vivian B Fernandes, David Ma, John Moore, Robert M Graham.   

Abstract

Severe thrombocytopenia in association with G-CSF therapy is extremely rare. Here we report a case of profound thrombocytopenia in a 57-year-old male with refractory cardiac ischemia, who received G-CSF during an angiogenesis trial. After 5 days of G-CSF therapy (10 microg/kg/day) the platelet count fell progressively to a nadir of 5x10(9)/L. The patient received steroid, immunoglobulin and platelet support and recovered without sequelae. Subsequent investigations suggested an underlying immune-mediated thrombocytopenia, which we hypothesize was exacerbated by G-CSF therapy. Copyright (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17034024     DOI: 10.1002/ajh.20787

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  4 in total

1.  Filgrastim induced thrombocytopenia.

Authors:  Ghazal Kango; Faysal Haroun
Journal:  BMJ Case Rep       Date:  2020-06-30

2.  G-CSF-induced severe thrombocytopenia in a healthy donor: A rare case report.

Authors:  Xuan Lu; Yu Wu; Huafang Wang; Linghui Xia
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.889

Review 3.  Side effects of cytokines approved for therapy.

Authors:  Brian A Baldo
Journal:  Drug Saf       Date:  2014-11       Impact factor: 5.606

4.  Transient thrombocytopenia in a cat following G-CSF treatment.

Authors:  Kyeong-Bo Kim; Ju-Hyun An; Jeong-Hwa Lee; Su-Min Park; Hyung Kyu Chae; Woo-Jin Song; Hwa-Young Youn
Journal:  Vet Med Sci       Date:  2021-12-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.